Kyowa Hakko advances pro-and-prebiotics knowledge, spotlights Immuse postbiotic
26 May 2022 --- More consumers are using a range of supplements to ensure they get the necessary ingredients to fortify and manage their health, according to Kyowa Hakko.
“Educating consumers and proving the efficacy of branded ingredients will play a significant role in future innovation,” Maria Stanieich, marketing manager at Kyowa Hakko US, tells NutritionInsight.
The company projects there will be continued demand for scientifically proven and clinically safe ingredients to attract and build trust. With this in mind, Kyowa Hakko is advancing awareness of its postbiotic Immuse product and knowledge on probiotics and prebiotics.
Unraveling how microorganisms work
Researchers are still unraveling exactly how probiotics, prebiotics and postbiotics impact and interact with the biological systems, Stanieich says.
“It has become evident that the colonies of microbiota living in and on the human body actively impact our health and play a significant role in maintaining homeostasis.”
“Deemed stable in various applications including tablets, capsules and gummy formulations, Immuse is beneficial for the immune system.”
Educating industry
In a bid to further education across industry, the company is bringing Dr. Collin Hill, as a new member of Kyowa Hakko’s Immuse Scientific Advisory Board.
Where consumers are concerned, Kyowa Hakko details that consumers are more aware of the importance of immune health, but they are also more knowledgeable, better informed and as a result, more skeptical.
“They are doing their research and want to see scientific evidence and clinical research validating a product’s effectiveness when shopping for an immune support supplement,” details Stanieich.
Spotlighting Immuse LC-Plasma strain
According to Stanieich, healthy gut nutrition that supports the immune system includes postbiotics, the latest category of ‘biotics’ which sees a lot of interest in growth in the marketplace.
Immuse LC-Plasma, a postbiotic, is pegged as an immune support ingredient with clinical data to promote immune health and help maintain physical condition.
“The microbes in postbiotics are not alive,” says Stanieich. “Therefore, the safety of postbiotics for their intended use must be demonstrated and Immuse LC-Plasma is a strain of good bacteria as it interacts well with the gut.”
“Rather than interacting with the microbiota in your large intestine, Immuse meets with a significant, influential immune cell located within the Peyer’s patch of the small intestine. It is the first strain of bacteria clinically shown to activate plasmacytoid dendritic cells (pDCs) directly, a rare subset of immune cells that act as leaders of the immune system.”
The company adds that Immuse is backed by 29 published studies, including 14 human trials consisting of 12 efficacy studies and two safety studies.
“These claims have been reviewed and vetted by our scientific and regulatory consultants,” Stanieich notes.
Previously, a Health-Ade executive pegged prebiotics as “more beneficial” for gut microbiome than probiotics.
By Nicole Kerr
To contact our editorial team please email us at editorial@cnsmedia.com
Subscribe now to receive the latest news directly into your inbox.